A randomized double‐blind, placebo‐controlled clinical phase IIa trial on safety, immunomodulatory effects and pharmacokinetics of EA‐230 during experimental human endotoxaemia

AIMS: EA‐230 is a human chorionic gonadotropin hormone‐derived linear tetrapeptide, developed for the treatment of systemic inflammation‐related disorders. EA‐230 has shown promising immunomodulatory and tissue‐protective effects in animals and an excellent safety profile in human phase I studies th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Main Authors: van Groenendael, Roger, Kox, Matthijs, Leijte, Guus, Koeneman, Bouke, Gerretsen, Jelle, van Eijk, Lucas, Pickkers, Peter
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595370/
https://ncbi.nlm.nih.gov/pubmed/30919998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13941
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares